01—Abstract
Summary
Summary of the 8-K filed February 10, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora filed this Form 8-K on February 10, 2026 to recast its fiscal 2025 segment disclosures to match a new reporting structure.
The change does not alter consolidated results. The company's audited financial statements in the FY2025 Form 10-K (filed November 25, 2025) are not restated, and the filing does not update that 10-K for later events. Exhibit 99.1 contains revised Items 1, 7, and 8 of the 10-K, along with a new Ernst & Young consent (Exhibit 23.1).
The revised structure, effective with the fiscal Q1 2026 10-Q filed February 4, 2026, has three groupings. U.S. Healthcare Solutions is U.S. Human Health excluding legacy U.S. Consulting Services. International Healthcare Solutions includes Alliance Healthcare, Innomar, World Courier, and strategic components of PharmaLex.
"Other" is not a reportable segment. It holds businesses for which Cencora has begun exploring strategic alternatives: MWI Animal Health, Profarma, U.S. Consulting Services, and the remaining PharmaLex components. The company says this follows a strategic review aimed at aligning the portfolio with its growth priorities.
For investors, the key takeaway is that the recast improves visibility into the core U.S. and international distribution businesses and flags businesses that may be sold or otherwise separated. The excerpt provided is truncated before the recast segment revenue and operating income tables, so this summary does not quantify the new segment figures.
Those numbers should be read from Exhibit 99.1 directly. The filing also does not discuss the financial impact of any potential divestitures.
02—Key points
Key Highlights
- Segment recast only: the 8-K revises segment presentation in FY2025 10-K Items 1, 7, and 8 and does not restate audited consolidated financial statements or modify prior disclosures beyond the segment change.
- New reporting structure: U.S. Healthcare Solutions, International Healthcare Solutions, and Other (not a reportable segment), effective with the fiscal Q1 2026 10-Q filed February 4, 2026.
- Strategic alternatives for 'Other': MWI Animal Health, Profarma, U.S. Consulting Services, and remaining PharmaLex components are being separated into a group where Cencora has begun exploring strategic alternatives, signaling possible divestitures.
- Re-cut of PharmaLex: strategic components move into International Healthcare Solutions, while other components move to Other, following the $723.9 million PharmaLex goodwill impairment recorded in FY2025.
- Baseline FY2025 consolidated results (unchanged by this filing): revenue of $321.3 billion (+9.3%), operating income of $2.63 billion, and net income attributable to Cencora of $1.55 billion.
- Ernst & Young consent is included, and the auditor's report date for Notes 1 and 14 is February 10, 2026, indicating those notes were updated for the recast.
03—Questions
Frequently Asked Questions
Does this 8-K change Cencora's reported financial results?
No. The filing states that it does not amend or restate the audited consolidated financial statements in the FY2025 10-K. It only changes how segment results are presented. Consolidated revenue, operating income, net income, and balance sheet figures are unaffected.
Why did Cencora reorganize its segments?
The company says a strategic review was undertaken to align the business with its growth priorities. As a result, it reorganized certain business components into U.S. Healthcare Solutions, International Healthcare Solutions, and Other.
What does it mean that some businesses are exploring 'strategic alternatives'?
Cencora has begun exploring strategic alternatives for MWI Animal Health, Profarma, U.S. Consulting Services, and certain PharmaLex components. This language typically indicates potential sale, spin-off, or other separation, but the filing does not confirm any specific transaction or timeline.
Where can investors find the revised segment numbers?
The revised segment results are in Exhibit 99.1, which contains recast Items 1, 7, and 8 of the FY2025 10-K. The excerpt reviewed here is truncated before those segment tables, so investors should consult the full exhibit. For developments after the 10-K, the company directs readers to its fiscal Q1 2026 10-Q.
How does this change affect the outlook for U.S. versus international performance?
The recast separates the core U.S. distribution business from international operations and the non-core Other businesses. This gives investors a cleaner view of the U.S. Healthcare Solutions segment, which drove most of FY2025 revenue growth, and of International Healthcare Solutions, which includes Alliance Healthcare, World Courier, and Innomar. Because the restated segment figures are not included in the excerpt, specific growth comparisons cannot be drawn from this filing alone.
04—Continue